Research News and Research

RSS

World-first dialysis study set to reduce health costs

The results of a world-first controlled trial of dialysis start-time in patients with Stage V chronic kidney disease is set to have major impact on the cost and infrastructure of chronic kidney disease (CKD) treatment and dialysis services.

20 Jul 2010

Prostate cancer: To screen or not to screen

Men with a family history of prostate cancer who are confused about whether to undergo controversial screening could soon have access to an online resource to have their questions answered.

20 Jul 2010

New & improved rotavirus vaccine to be trialed in Melbourne

Now a vaccine is being developed against rotavirus in Melbourne. At present Australian children were given rotavirus vaccine at the age of six to eight weeks since 2007. This new vaccine will be applicable to infants from birth.

20 Jul 2010

New development in flu prevention & treatment

In a groundbreaking development, scientists at the Australian National University in Canberra have found the key to the mutation of the flu virus. This may allow the manufacturing of a life-long vaccine stopping the need for repeated vaccinations. The scientists reveal that they have found a protein in the virus that changes or mutates in order to develop resistance in the virus.

20 Jul 2010

HIV – Rising menace

Nevirapine is considered to be an effective drug that can prevent HIV infection in babies born to mothers with HIV. However a new study shows that only about half of babies born to mothers with HIV receive the drug. The study appeared in the July 21 HIV/AIDS themed issue of the Journal of the American Medical Association.

20 Jul 2010

Forest Laboratories reports first-quarter diluted EPS of $0.39

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.39 in the first quarter of fiscal 2011. Excluding the charge related to the United States Department of Justice investigations described below, and a charge of $50.0 million, or $0.17 per share net of tax, for a new product licensing fee, non-GAAP earnings per share for the first fiscal quarter were $0.95 per share.

20 Jul 2010

ARUP announces new version of Septin 9 methylated DNA test

ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, today announced it is offering the Septin 9 methylated DNA test, a new blood-based colorectal cancer screening method. While ARUP is not the first laboratory to offer this test, this new version, developed and validated independently by ARUP, is clinically proven to detect a higher proportion of colorectal cancers than Septin 9 tests developed by other companies.

20 Jul 2010

Arcion reports top-line results from ARC-4558 Phase 2b clinical trial for painful diabetic neuropathy

Arcion Therapeutics, a venture backed clinical stage biotechnology company developing topical therapies for chronic pain, today announced top-line results from a successful Phase 2b double-blind, randomized, placebo-controlled clinical trial of its lead topical pain candidate, ARC-4558, in adult patients with painful diabetic neuropathy (PDN). Arcion recently held an End of Phase 2 meeting with the United States Food and Drug Administration (FDA) and the ARC-4558 program is now poised to enter Phase 3 studies.

20 Jul 2010

International Stem Cell, IBVI sign letter of intent concerning funding, establishment of ISCO India

International Stem Cell Corporation, www.internationalstemcell.com, and Insight Bioventures India Private Limited, announced today that they have signed a letter of intent concerning funding and establishment of an Indian affiliate of ISCO. The goal is to establish world-class development and manufacturing operations for ISCO's research and pharmaceutical products in India, including its Lifeline Cell Technology research products and human corneal tissue, CytoCor, for treatment of corneal vision impairment and testing of chemicals.

20 Jul 2010

Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.

20 Jul 2010

ARUP enters partnership to offer deCODE's DNA-based prostate cancer risk assessment test

deCODE genetics and ARUP Laboratories today announced a partnership through which ARUP will offer deCODE's DNA-based prostate cancer risk assessment test to its clients nationwide.

20 Jul 2010

Fero Industries provides comments concerning FDA advisory panel recommendation on diabetes drug Avandia

Fero Industries, Inc. is pleased to provide these comments regarding the recent Food and Drug Administration advisory panel recommendation concerning the GlaxoSmithKline PLC diabetes drug Avandia. The FDA advisory panel has recommended that the agency keep diabetes drug Avandia on the U.S. market despite data clearly showing an increased risk of a heart attack and that GSK covered up their own research that first identified the problem.

20 Jul 2010

Acorda Therapeutics awarded $1M C-TRIP grant to support research on GGF2

Acorda Therapeutics, Inc. today announced the National Heart, Lung, and Blood Institute has awarded a $1 million Cardiac Translational Research Implementation Program grant to support research on Glial Growth Factor 2, a novel investigational agent for the treatment of patients with heart failure under development at Acorda.

20 Jul 2010

Frameless radiosurgery can treat most sensitive regions of brain: Study

While four in 10 clinicians use frameless radiosurgery exclusively to treat cranial indications, user data collected at the 5th International Conference of the Novalis Circle, held last month in Munich, Germany, shows that there are still significant opportunities to increase utilization of the effective treatment approach.

20 Jul 2010

Meridian Bioscience completes acquisition of Bioline group of companies

Meridian Bioscience, Inc., Cincinnati, Ohio announces that effective today it will have completed the purchase of all the outstanding capital stock of the Bioline group of companies consisting of Bioline Ltd (UK), Bioline GmbH (Germany), Bioline (Aust) Pty Ltd (Australia), Bioline Reagents Ltd, and Bioline USA, Inc for $23.3 million in cash on hand.

20 Jul 2010

First Edition: July 20, 2010

Today's headlines reflect more analysis and debate regarding continuing health reform implementation efforts.

20 Jul 2010

Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

Researchers who conducted a study testing a vaginal microbicide with an antiretroviral (ARV) drug called tenofovir found its use before and after sex was significantly more protective against HIV infection than a placebo gel among women at high risk of HIV. Results of the study, known as CAPRISA 004, are to be reported at the International AIDS Conference (AIDS 2010) in Vienna and published online by the journal Science.

20 Jul 2010

Quantitative capabilities of Helicos' single-molecule sequencing technology demonstrated

Helicos BioSciences Corporation today announced a publication entitled "Amplification-free digital gene expression profiling from minute cell quantities" appearing on line in Nature Methods co-authored by Dr. Daniel A. Haber and colleagues from Massachusetts General Hospital. The paper demonstrates the quantitative capabilities of Helicos' single-molecule sequencing technology and its potential to reveal important genomic differences when minimal numbers of cells are available for analysis.

20 Jul 2010

Diffused ultraviolet radiation penetrates beach umbrellas

A team of researchers from the University of Valencia (UV) has proven that 34% of ultraviolet radiation filters through under beach umbrellas. According to what is published in the journal Photochemistry and Photobiology, umbrellas intercept the full direct flow that comes from the Sun, but not the diffused radiation that penetrates through from the sides.

20 Jul 2010

Nontargeted opt-out screening associated with newly identified HIV-infected patients: Study

The use of routine HIV screening in a hospital emergency department, which patients had the option to decline, was associated with only a modest increase in the number of patients with newly diagnosed HIV infection, compared to physician-directed diagnostic rapid HIV testing, according to a study in the July 21 issue of JAMA, a theme issue on HIV/AIDS.

20 Jul 2010

Research News and Research

World-first dialysis study set to reduce health costs

Prostate cancer: To screen or not to screen

New & improved rotavirus vaccine to be trialed in Melbourne

New development in flu prevention & treatment

HIV – Rising menace

Forest Laboratories reports first-quarter diluted EPS of $0.39

ARUP announces new version of Septin 9 methylated DNA test

Arcion reports top-line results from ARC-4558 Phase 2b clinical trial for painful diabetic neuropathy

International Stem Cell, IBVI sign letter of intent concerning funding, establishment of ISCO India

Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer

ARUP enters partnership to offer deCODE's DNA-based prostate cancer risk assessment test

Fero Industries provides comments concerning FDA advisory panel recommendation on diabetes drug Avandia

Acorda Therapeutics awarded $1M C-TRIP grant to support research on GGF2

Frameless radiosurgery can treat most sensitive regions of brain: Study

Meridian Bioscience completes acquisition of Bioline group of companies

First Edition: July 20, 2010

Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

Quantitative capabilities of Helicos' single-molecule sequencing technology demonstrated

Diffused ultraviolet radiation penetrates beach umbrellas

Nontargeted opt-out screening associated with newly identified HIV-infected patients: Study

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence